We report the characterization of two distinct binding sites with receptor characteristics for leukotriene (LT)D 4 and LTC 4 in membranes from human lung parenchyma. The use of S-decylglutathione allowed us to characterize a previously unidentified high affinity binding site for LTC 4 . Computerized analysis of binding data revealed that each leukotriene interacts with two distinct classes of binding sites (K d ϭ 0.015 and 105 nM for LTC 4 and 0.023 and 230 nM for LTD 4 ) and that despite crossreactivity, the two high affinity sites are different entities. LTD 4 binding sites displayed features of G protein-coupled receptors, whereas LTC 4 binding sites did not show any significant modulation by guanosine-5Ј-(␤,␥-imido)triphosphate or stimulation of GTPase activity. The antagonists ICI 198,615 and SKF 104353 were unselective for the high and low affinity states of LTD 4 receptor, whereas only SKF 104353 was able to recognize the two [ 3 H]LTC 4 binding sites although with different affinities. These data indicate that in human lung parenchyma, LTD 4 and LTC 4 recognize two different binding sites; these binding sites are different entities; and for LTD 4 , the two binding sites represent the interconvertible affinity states of a G proteincoupled receptor, whereas for LTC 4 , the high affinity site is likely to be a specific LTC 4 receptor.
Cysteinyl-LTs are a family of biologically active compounds derived from arachidonic acid via the 5-lipoxygenase pathway (Murphy et al., 1979) ; they have been shown to be potent bronchoconstrictors (Dahlén et al., 1980) in both normal people and asthma patients (Barnes et al., 1984) . Therefore, the main pathophysiological role of cysteinyl-LTs lies in asthma (Piper et al., 1991) , which is considered a chronic inflammatory condition characterized not only by bronchial constriction but also by bronchial hyperresponsiveness, mucus hypersecretion, and plasma extravasation. In the latter phenomena, the lung parenchyma plays a fundamental role (Chanarin and Johnston, 1994) . For these reasons, an increasing number of studies aimed at the pharmacological characterization of Cys-LT receptors have been performed in the respiratory system of different species.
It has been demonstrated that at least two different Cys-LT receptors exist in guinea pig airways: one predominantly activated by LTD 4 and LTE 4 , and a second predominantly activated by LTC 4 . The former is sensitive to the so-called classic antagonists, the most studied of which are SKF 104353, MK 571, ICI 198,615, and Ro 24 -5913 (Salmon and Garland, 1991) , and has been named Cys-LT 1 , whereas the latter, Cys-LT 2 , is insensitive to the same antagonists (Coleman et al., 1995) . The nature of Cys-LT receptors in human airways has been a matter of debate; it is widely accepted that LTC 4 binds to a variety of nonreceptor sites (i.e., enzymes involved in its synthesis and metabolism and transporters) (Keppler, 1992; Nicholson et al., 1992; Metters et al., 1994) . So far, such binding proteins have impaired the identification of its specific receptor by ligand-binding studies.
The aim of the current study was to characterize the nature and number of cysteinyl-LT binding sites in HLPM. In fact, it has already been demonstrated in this tissue that under controlled metabolic conditions, both LTC 4 and LTD 4 are able to contract isolated human lung strips (Gardiner and Cuthbert, 1988) . We used a variety of experimental protocols for ligand binding studies in addition to computer modeling of binding data and GTPase activation. We report the identification of two distinct high affinity binding sites for LTC 4 and LTD 4 that bear the characteristics of specific receptors. were purchased from DuPont-New England Nuclear (Boston, MA). [␥- 32 P]GTP (Ͼ5000 Ci/mmol) was purchased from Amersham International (Little Chalfont, Buckinghamshire, UK). LTC 4 , LTD 4 , and LTE 4 were obtained from Cayman Chemical (Ann Arbor, MI). SKF 104353 was kindly provided by SmithKline and Beecham (King of Prussia, PA). ICI 198,615 was kindly provided by Zeneca (Basiglio, Italy). Gpp(NH)p, S-decyl-GSH, cysteine, glycine, boric acid, serine, HEPES, and the reagents used for GTPase assay were purchased from Sigma Chemical (St. Louis, MO). Filtercount and Ultima Gold were from Packard Instruments (Meriden, CT). All the reagents used in HPLC analysis were of analytical grade and purchased from Carlo Erba (Milan, Italy), as were GF/C Whatman fiber-glass filters.
Experimental Procedures Materials

Preparation of Human Lung Membranes
Crude membranes were prepared from macroscopically normal human lung specimens that had removed during thoracotomy for lung cancer as described previously (Rovati et al., 1985) . Briefly, specimens were minced and homogenized at 4°in 10 mM HEPES buffer, pH 7.4 (1:24, w/v), with a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). The homogenate was centrifuged at 770 ϫ g for 10 min, and the supernatant was centrifuged at 27,000 ϫ g for 20 min. The pellet was resuspended in the same buffer, centrifuged under the same condition and resuspended in 1/20th of the homogenization volume. The membrane aliquots were frozen at Ϫ80°and stored for no longer than 3 months. Protein content was determined with the Bradford dye-binding protein assay (Pierce, Rockford, IL). Before use, serine/borate complex (40 mM), prepared as an equimolar solution of serine and boric acid, cysteine (10 mM), and glycine (10 mM) were added to the membrane suspension to avoid cysteinyl-LT metabolism.
Reversed-Phase HPLC
Before use, labeled and unlabeled leukotriene purity always was assessed by reversed-phase HPLC. Only leukotrienes with a purity grade Ն90% were used. The Beckman Instruments (Columbia, MD) HPLC system was equipped with a 110B Solvent Delivery Module, ODS Ultrasphere C18 column (5 m, 4.6 mm ϫ 25 cm), and a Programmable Detector Module 166 set at 280 nm. Both labeled and unlabeled leukotrienes were eluted isocratically with a filtered and degassed mixture of CH 3 OH/H 2 O/CH 3 COOH (65:35:0.02), adjusted at pH 5.8 with NH 4 OH, at a flow rate of 1 ml/min. To check the purity of tritiated leukotrienes, fractions were collected every 30 sec, and the radioactivity profile was assessed by liquid scintillation counting (Ultima Gold; Packard, Meriden, CT).
Binding Studies
Equilibrium binding studies were performed at 25°for 30 min with 0.02-0.5 nM [
3 H]LTC 4 or [ 3 H]LTD 4 and unlabeled homologous and heterologous ligands at the indicated concentrations. Heterologous competition curves were performed with 0.5 nM labeled ligand. HLPM (0.25 mg/sample), 10 mM HEPES-KOH, pH 7.4, 1 mM CaCl 2 , and 10 M S-decyl-GSH (unless otherwise indicated) were added to the incubation mixture to achieve a final volume of 250 l. Gpp(NH)p was used at a concentration of 30 M where indicated. Unbound ligand was separated from bound ligand by rapid vacuum filtration (Brandel Cell Harvester) onto glass-fiber GF/C filters soaked in 2.5% polyvinyl alcohol, and the filters were washed twice with 4 ml of HEPES buffer at 4°. Radioactivity was then measured in a liquid scintillation counter (Filter Count; Packard). Nonspecific binding was 35-50% and 25-30% of the total binding (at 0.5 nM labeled ligand) for LTD 4 and LTC 4 , respectively. It was calculated by LIGAND as one of the unknown parameters of the model. Each experiment was performed at least three times in triplicate.
Protocol Optimization and Computer Analysis
The program DESIGN (Rovati et al., 1988) was used to optimize the binding protocols by selecting the lowest number of most appropriate concentrations in mixed-type curves (Rovati et al., 1991) and multiligand experiments (Rovati et al., 1990) .
Mixed-type curves. The first three to five concentrations (0.02-0.5 nM) in the curves were obtained using increasing concentrations of labeled ligand (saturation part of the curve), whereas the last three to five concentrations (1 nM to 1 M) were obtained by adding increasing concentrations of unlabeled ligand to a fixed concentration of labeled ligand (homologous competition part of the curve). By effectively combining both saturation and competition protocols in a single curve, high concentrations of the ligands can be reached without consumption of excessive amounts of labeled ligand (competition part of the curve), yet there will be adequate radioactivity in the lower concentration range (saturation part of the curve). This type of protocol is useful when dealing with labeled ligands with a low specific activity (typically tritiated ligands) that interact with high affinity binding sites (Rovati, 1993) .
Multiligand protocols. With this type of protocol, the concentrations of both labeled and unlabeled ligands can be varied simultaneously. By definition, these designs allow the use of any combination of two (or more) ligands in each reaction tube; therefore, a multiligand design potentially includes all possible combinations of concentrations of labeled and unlabeled ligand. This three-dimensional binding "surface" may be regarded either as a family of doseresponse curves for ligand 1 in the presence of increasing concentrations of ligand 2 or as a family of dose-response curves for ligand 2 in the presence of increasing concentrations of ligand 1. We performed a series of saturation or mixed curves (e.g., with [ 3 H]LTD 4 ), each in the presence of a fixed concentration of a second unlabeled compound (LTC 4 or an antagonist). In fact, to study an unlabeled ligand (regardless of its K i value) with a classic heterologous competition curve, a concentration of the labeled ligand must be used that is lower than its K d , or the so-called self-displacement by the same labeled ligand occurs, thus preventing interaction of the unlabeled ligand with that site (Rovati, 1993) . On the other hand, such a low concentration of labeled ligand might yield an amount of bound radioactivity extremely low. To overcome this limit, we extensively used the multiligand protocols.
Computer analysis. Analysis of binding data was performed using the program LIGAND (Munson and Rodbard, 1980) . The computerized analysis of the data through the use of LIGAND has several advantages: it allows (1) analysis of the mixed-type curves and multiligand designs; (2) simultaneous analysis of several experiments, thus pooling information from different curves; (3) testing of different models of increasing complexity (i.e., one-site, two-site, possible cross-reactivity, and so on) and selection of the most appropriate model using the F test for the extra sum of square principle (Draper and Smith, 1966) ; (4) Binding is expressed as the ratio of bound ligand concentration to total ligand concentration (B/T, dimensionless) versus the logarithm of total ligand concentration (log T). B (in M) is the sum of labeled, nonlabeled, and nonspecific binding; T (in M) is the sum of labeled and nonlabeled ligand incubated. This graphic representation was chosen because it is the only way to present mixed curves (which cannot be presented in the classic form of percentage specific binding) and it allows a direct comparison of mixed, multiligand, and competition curves. All the curves shown were computer generated.
GTPase Activity
The following standard conditions were used to measure the release of 32 P i from [␥-32 P]GTP on the basis of the method of Cassel and Selinger (1976) . The assay system contained 1 M [␥-32 P]GTP (5 Ci/mmol), 2 mM MgCl 2 , 1 mM 5Ј-adenylylimidophosphate, 0.5 mM ATP, 10 mM creatine phosphate, 10 mM creatine phosphokinase, 1 mM dithiothreitol, 0.1 mM EDTA, 0.5 mM ouabain, 150 mM NaCl, and 10 mM Tris⅐HCl, pH 7.4, in a final volume of 0.1 ml. Low affinity hydrolysis of [␥- 32 P]GTP (high K m GTPase activity) was assessed by incubating parallel tubes in the presence of 50 mM GTP and was subtracted from the total GTPase activity to calculate high affinity GTPase hydrolysis. The reaction was initiated by the addition of HLPM (0.005 mg of protein) to the mixture at 37°and terminated after a 20-min incubation through removal of the tubes to ice for 3 min and the addition of 0.5% (w/v) active charcoal in H 3 PO 4 , pH 2.2-2.3, giving a total volume of 1 ml. The 32 P i formed was separated from the nonhydrolyzed nucleotide-bound phosphate by centrifugation at 11,000 ϫ g for 5 min. Aliquots (0.5 ml) of the supernatant were removed form each tube and added to scintillation liquid (Ultima Gold; Packard) for radioactivity counting. were performed in the absence and presence of 10 M S-decyl-GSH (Fig. 1) . In the absence of S-decyl-GSH, only one low affinity class of sites was detectable in most of the experiments with [ 3 H]LTC 4 (Fig. 1A) , whereas in the presence of S-decyl-GSH, at least two classes of sites were present: one with high affinity and low capacity and a second with low affinity and high capacity ( (Fig. 2) , revealing an interaction with a high and a low affinity class of sites ( Table 2 ). The heterologous competition curves for LTC 4 and LTD 4 also are shown and appear to be monophasic ( Fig. 2) with K i values in the low affinity range ( Fig. 3 ; for the sake of clarity, only the effect of the highest concentration (i.e., 10 nM) of unlabeled ligand is shown]. The K i values of each LT versus the sites labeled by the other leukotriene were obtained through simultaneous computer analysis of a family of four different curves (control plus the three multiligand curves at the above indicated concentrations) for each labeled ligand (Table 2) . Furthermore, for both ligands, we tested the model that assumes cross-reactivity versus the simpler model that rules it out, by means of the F test (see Experimental Procedures) and found that the former was significantly better ( p Ͻ 0.05). Thus, taken together, these results indicated that the unlabeled ligand was able to significantly decrease the binding of the labeled LT.
Results
To validate the results, we simulated (MacSIMUL; G. E. Rovati and P. J. Munson) the theoretical model for the simultaneous interaction of two ligands, each with two different binding sites. In particular, we hypothesized the interaction of a ligand, with the binding characteristic of LTD 4 (K i1 ϭ 7.7 nM, K i2 ϭ 46 nM; (Fig. 4) was able to significantly ( p Ͻ 0.05) stimulate the receptorinduced hydrolysis of GTP (Fig. 8A) . Furthermore, the receptor antagonist SKF 104353 (10 M) was able to completely inhibit LTD 4 -induced stimulation (Fig. 8A) , and LTD 4 stimulated the GTPase activity in a dose-dependent manner (Fig.  8B) .
Discussion
Despite the efforts by many researchers, no Cys-LT receptor has been successfully purified or cloned. This might be due to the fact that these receptors are present in such a scarce amount that even their detection by binding techniques is sometimes difficult. Moreover, it is well known that in cellular membranes, LTC 4 binds predominantly to a number of nonreceptor sites, such as glutathione-S-transferase (Metters et al., 1994; Sun et al., 1986) , LTC 4 synthase (Nicholson et al., 1992) , or transport proteins (Keppler, 1992) . Therefore, we used S-decyl-GSH, a ligand structurally similar to LTC 4 but devoid of either agonist or antagonist activities (Norman et al., 1987; Sala et al., 1990) , to inhibit binding to such nonreceptor sites and thus unmask a putative high affinity LTC 4 receptor. In fact, because LTC 4 is able to contract human isolated lung strips with a potency similar to LTD 4 (Gardiner and Cuthbert, 1988) , it is likely that LTC 4 , as well as LTD 4 , should have a high affinity binding site.
Although only one low affinity/high capacity site was detectable in most experiments in the absence of S-decyl-GSH (Fig. 1A) (Metters et al., 1994) , as reported in practically all the previous [ 3 H]LTC 4 binding studies (Pong et al., 1983; Nicosia et al., 1984; Rovati et al., 1985; Civelli et al., 1987; Norman et al., 1987) . Indeed, it should be considered that the low affinity binding site for LTC 4 could correspond to the ATP-dependent LTC 4 export pump. This MRP gene-encoded protein is strongly expressed in normal lung parenchyma (Narasaki et al., 1996) and has a K m value of 97 nM (Leier et al., 1994) that is compatible with the K d value of 105 nM (Table 2) estimated for the low affinity binding site of LTC 4 . Moreover, this site has a B max value that is 14% of the value obtained in the absence of S-decyl-GSH, indicating that S-decyl-GSH is able to inhibit most of the nonreceptor binding. However, we cannot completely rule out the hypothesis that this site might be a mixture of LTD 4 receptors and nonreceptor proteins.
As expected for a ligand with low affinity for enzymes such as glutathione-S-transferase (Sun et al., 1986) To investigate whether these sites coincide or are separate entities, a series of heterologous competition curves using LTC 4 and LTD 4 were performed. Both LTC 4 and LTD 4 het- erologous competition curves appear to be monophasic (Fig.  2) , suggesting that each ligand is able to compete with comparable affinities with the low affinity sites labeled by the other one (Table 2) . However, in the case of low specific activity ligands (see Experimental Procedures), this type of experimental protocol does not allow the study of the influence of the nonlabeled heterologous ligand on the high affinity sites labeled by the labeled ligand (Rovati, 1993) . Therefore, heterologous competition curve can provide information only on the low affinity site.
Hence, we applied a multiligand protocol to study the possible influence of LTC 4 on the high affinity sites labeled by [ 3 H]LTD 4 and vice versa (Fig. 3) (Fig. 4) that were almost superimposable with the experimental ones (Fig. 3) , thus validating the conclusion drawn from analysis of the real data.
These results strongly suggest that the high affinity site labeled by [ 3 H]LTC 4 is a different entity from the site labeled by [ 3 H]LTD 4 and that there is cross-reactivity between LTD 4 and LTC 4 high affinity sites. Indeed, it is known from functional studies that in some tissues, so-called classic LTD 4 antagonists failed to block the effect of high doses of LTD 4 (Gardiner et al., 1990) . This provides evidence that LTD 4 response includes an antagonist resistant component in some tissues (Gardiner et al., 1994) (Table 2) ; therefore, the LTE 4 response also is in agreement with the hypothesis that two distinct receptors exist in HLPM: one more specific for LTD 4 /LTE 4 and one more specific for LTC 4 .
To investigate the nature of LTC 4 and LTD 4 putative receptors in HLPM, we studied their potential coupling to a G protein by performing mixed binding curves in the absence and presence of Gpp(NH)p, a stable GTP analog. Gpp(NH)p was able to completely shift [ 3 H]LTD 4 binding from the high affinity site to its low affinity site (Fig. 5B) , suggesting that these sites represent two interconvertible affinity states of the same receptor and confirming that [ 3 H]LTD 4 binds to a G protein-coupled receptor (Mong et al., 1986; Crooke et al., 1989) . On the other hand, the same Gpp(NH)p concentration was not able to substantially affect [ 3 H]LTC 4 binding (Fig.  5A) (Fig. 8A) . Furthermore, LTD 4 response is concentration dependent (Fig. 8B) , and the receptor antagonist SKF 104353 is able to significantly inhibit LTD 4 -induced stimulation of the enzyme (Fig. 8A) . Therefore, these data indicate that LTD 4 receptor is indeed coupled to a G protein, whereas the putative specific LTC 4 receptor in HLPM is not coupled to any G protein. A further, but unlikely, hypothesis is that LTC 4 binds to a G protein-coupled receptor (different from that of LTD 4 ) but behaves as an antagonist, thus being unable to activate GTPase and displaying a GTP-insensitive binding.
A number of antagonists are available for research, and some are undergoing clinical evaluation. We used two of them to study the pharmacological profile of the putative LTD 4 and LTC 4 receptors. As pure antagonists, they should not distinguish between the high and low affinity state of a G protein-coupled receptor, such as that for LTD 4 (De Lean et al., 1980; Lefkowitz et al., 1993) . In fact, the multiligand experiment performed with SKF 104353 (Fig. 6B) confirmed that as expected, this compound interacts with both the high and low affinity states of the LTD 4 receptor with the same affinity. Furthermore, the dissociation constant computed only from the competition curve (Fig. 6A ) and the one computed from the multiligand curves are substantially identical (Table 4 Taken together, these data indicate that in human lung parenchyma (Fig. 9) , (1) parenchyma (Gardiner and Cuthbert, 1988) , to which a high affinity binding site must correspond.
In conclusion, the characterization of the Cys-LT receptors in human lung parenchyma, which is important in the pathogenesis of asthma, may foster the identification of a novel cysteinyl-LT antagonist with an ideal pharmacological profile to be used in the therapy of this chronic disease. The existence of a specific receptor for LTC 4 in this tissue implies that an ideal antagonist should be able to recognize and antagonize not only the LTD 4 receptor but also that specific for LTC 4 . In fact, all the antagonists developed up to now, including the dual antagonist BAY u9773, are unable to completely reverse the effect of high doses of LTD 4 or LTC 4 in some tissues (Gardiner et al., 1994) , such as human lung, thus limiting the therapeutical efficacy of this class of drugs. 
